



Corporate Presentation

BIO

CEO & INVESTOR CONFERENCE

New York, NY

February 13, 2018

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.


Mission

To Build an Integrated Pharmaceutical Company Serving 1.5 billion People in China with High Quality and Affordable Products while Addressing the U.S. and Global Markets Cost-Effectively

Acquisition from Sandoz 29 ANDA Products and Pipeline


25 FDA Approved, 4 Pending FDA Approval ANDAs

Diverse Portfolio Across Attractive Therapeutic Area



Historical Opportunity for FDA-Approved ANDAs in China

Rapidly Establishing A Lead Position in China's >\$100 bn Small Molecule Drug Market



Value Proposition

China, America, Synergy, Integration

A Unique Competitive Position to Capitalize the Opportunity

Cost-Pricing Pressure
Players Exit Generics
Market Needs



- Advanced Technology
- Science and Innovation
- FDA Standard
- Quality
- Market


Government Initiatives
Industry Consolidation
Market Needs



- Fast Growing Market
- Cost-effective Dev
- FDA/EMA Manufacturing
- CFDA new regulations
- Clinical Trials

ANDA Development Strategy and Plan

Self-Development and Partnering with Local Players



A Platform for Pursuing Additional Product Pipeline Portfolio

On the Top List in China with FDA ANDA Products and Pipeline with Opportunity for Rapid Growth


Greater China Rights

Acquired From SPPI




FDA ANDAs

Acquired From Sandoz
25 FDA Approved ANDAs
4 FDA Pending ANDAs



ENMD-2076, Global Rights

Innovative Drug Candidate
Target Therapy for Solid Tumors



China Market for ZEVALIN[®], MARQIBO[®], EVOMELA[™]

- **Strong IP position, greater China exclusivity, and significant technology barriers**
- **Minimal clinical, regulatory, and financial risks** as they are all FDA approved products, already sold in the U.S.
- The value of each of the products will increase incrementally as the applications get closer to marketing approval, and we expect to see **sustained growth** in market share after market entry
- **Address unmet medical needs.** Superior safety and efficacy benefits comparing to similar types of existing products; CFDA's priority review status, i.e. Evomela, may lead to fast track approval
- To be first and best in the class in China with significant competitive advantages



Collectively, \$148 million annual peak sales are forecast

The Market Potential in China

- **No form of melphalan, branded or generic, is currently available in China – EVOMELA will address an urgent medical need**
- CASI's import drug application for EVOMELA was granted **priority review** by the China FDA, acknowledging the urgent medical need and EVOMELA's therapeutic advantages to currently available therapeutics.
 - Lack of propylene glycol solvent which is related to certain safety events
 - Captisol formulation allows for increased stability when reconstituted for patient administration
- Annual incidence of multiple myeloma in China is estimated at 12,197 cases with a case mortality of 9,038 in 2015*
- **Annual peak sales are estimated to be over \$35 million, assuming ≥ 10% self-pay**

*<http://globocan.iarc.fr/Pages/online.aspx>

GLOBOCAN 2012: Estimated Cancer Incidence,
Mortality and Prevalence Worldwide in 2012

International Agency for Research on Cancer





The Market Potential in China

- Proprietary liposomal formulation of vincristine which improves the pharmacokinetics and pharmacodynamics of vincristine*
 - Higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues
- Annual incidence of leukemia in China is estimated at 75,300 cases with a mortality of 53,400 cases in 2015**
- **Annual peak sales are estimated to be over \$49 million, assuming a \geq 10% self-pay**

*Silverman, J and Deitcher S. Marqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine *Cancer Chemother Pharmacol* (2013) 71:555–564

**Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016 Mar-Apr;66(2):115-132.

The Market Potential in China

- Anti-CD20 antibody coupled to Yttrium-90
 - 83% ORR, 39% CR in relapsed or refractory, low-grade or follicular B-cell NHL
- Annual incidence of NHL in China is estimated at 83,790 new cases with a mortality of 50,100 cases in 2015*.
- ZEVALIN is expected to rapidly penetrate the Chinese market as the centralized structure of patient care in China results in a much less fragmented delivery system relative to other countries. In China, hospitals are the central facility of oncology patient care and physicians are likely to refer their patients for ZEVALIN treatment within the same hospital.
- **Annual peak sales are estimated to be \$64 million for FNHL, assuming a $\geq 10\%$ self-pay**

*Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-132.

Market for Entecavir

- Hepatitis B virus (HBV) infection remains a severe public health problem worldwide, with 2 billion people currently infected, 360 million having chronic infections and 600,000 deaths annually from either HBV-related liver disease or hepatocellular carcinoma.*
- In China, about 120 million people being hepatitis B surface antigen (HBsAg) carriers, 20 million suffering from chronic hepatitis B, and approximately 300,000 deaths each year caused by HBV-related infections.*
- Entecavir is a first line therapy for HBV infection; the average cost of treatment is ~\$800 dollars per patient in China;
- For 20 million patients, the market potential would be US\$16 bn dollars.

* <https://www.nature.com/articles/srep36186>

China Market for 6 Key ANDA Products

Key Products by 2016 (Estimated) Generic Sales in China

	Product	Indication	2016E Sales (in US\$)
1	Entecavir tablet	HBV Infection	1,490,000,000
2	Repaglinide tablet	Diabetes	225,000,000
3	Bisoprolol Fumarate tablet	Hypertension	205,000,000
4	Cilostazol tablet	peripheral vascular disease	65,000,000
5	Methimazole tablet	Hyperthyroidism	29,000,000
6	Tizanidine tablet	Muscular Relaxant	20,895,000
		Total Estimated Sales	US \$2.2 billion

* Based on China's PDB Database


U.S. Market for the 8 Key ANDA Products

Key Products by 2016 U.S. Sales*

	Product Name	Indications	Sandoz U.S. Sales 2016 (IMS data)	Overall U.S. Generic Sales 2016 (IMS data)
1	Midodrine	Hypotension	19,800,000	56,900,000
2	Triamterene / HCTZ cap	Hypertension, diuretic	4,600,000	54,000,000
3	Lisinopril tab	Hypertension	15,000,000	93,000,000
4	Bisoprolol Fumarate	Hypertension	8,400,000	22,000,000
5	Cilostazol tab	peripheral vascular disease	2,200,000	13,000,000
6	Diclofenac Potassium tab	OA, RA	5,400,000	27,000,000
7	Diclofenac Sodium tab	OA, RA	2,400,000	406,177,392
8	Nabumetone	RA	4,200,000	22,000,000
		Total Sales in US\$	\$62 million	\$694 million

* Based on IMS

On Fast Track for Growth and Expansion



Investment Highlights

- **Market:** Well-positioned to pursue significant and unprecedented market opportunities in China and the U.S.
- **Model:** Compelling business model with important U.S./China synergies and competitive advantage with efficiency and cost-effectiveness for drug development and commercialization
- **Product:** A strong and growing product pipeline developed under dual models of acquisition and internal development
- **Management:** An experienced, motivated leadership with track record of accomplishment in both U.S. and China
- **Finance:** Strong financial position, backed by successful venture fund and smart money, under careful financial management with low burn rate
- **Value Drivers:** Significant defined near-term value drivers supporting long term growth.



NASDAQ: CASI

www.casipharmaceuticals.com